Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

Despite antiretroviral therapy, proviral latency of human immunodeficiency virus type 1 (HIV-1) remains a principal obstacle to curing the infection [1]. Inducing the expression of latent genomes within resting CD4+ T cells is the primary strategy to clear this reservoir [2]. While histone deacetyla...

Descripción completa

Detalles Bibliográficos
Autores principales: Archin, NM, Liberty, AL, Kashuba, AD, Choudhary, SK, Kuruc, JD, Crooks, AM, Parker, DC, Anderson, EM, Kearney, MF, Strain, MC, Richman, DD, Hudgens, MG, Bosch, RJ, Coffin, JM, Eron, JJ, Hazuda, DJ, Margolis, DM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3704185/
https://www.ncbi.nlm.nih.gov/pubmed/22837004
http://dx.doi.org/10.1038/nature11286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3704185/
https://www.ncbi.nlm.nih.gov/pubmed/22837004
http://dx.doi.org/10.1038/nature11286

Ejemplares similares